Abiomed, Inc. reported unaudited revenue results for the third quarter of fiscal 2018. The company reported preliminary, unaudited, third quarter fiscal 2018 revenue of approximately $154 million, an increase of 34% compared to revenue of $114.7 million for the same period of fiscal 2017.

Preliminary fiscal 2018 guidance has been upgraded to approximately $582 million, an increase of approximately 31% from the prior year. This compares to prior fiscal 2018 guidance of $565 million to $575 million.